The Thai government has issued a compulsory license for production and importation of an inexpensive version of the HIV med efavirenz (called Sustiva in the U.S.), without consulting the drug’s patent-holding maker, Merck. In response, the company offered to cut the drug’s price and to discuss a “voluntary” generics license.